Myriad Genetics (MYGN) PT Lifted to $42 at Mizuho Securities Post Q1; Remains Sidelined

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. INTC
2. SPCX
3. ACN
4. DSX
5. GNK
6. SAN
7. TTEC
8. SNY
9. CART
10. DAL

Go back to Myriad Genetics (MYGN) PT Lifted to $42 at Mizuho Securities Post Q1; Remains Sidelined

Myriad Genetics (MYGN) PT Raised to $47 at Piper Jaffray

November 4, 2015 8:50 AM EST

Piper Jaffray analyst William Quirk reiterated an Overweight rating and boosted his price target on Myriad Genetics (NASDAQ: MYGN) to $47.00 (from $45.00) following Q1 beat.

Quirk commented, "Myriad's 1Q16 revenue increased 9% yoy to $183.5M, above consensus of $177.9M (PJC: $177.6M). Adjusted EPS of $0.41 was above consensus'... More

Myriad Genetics (MYGN) PT Up to $46 at Leerink Partners After Solid Q1

November 4, 2015 7:21 AM EST

Leerink Partners analyst Dan Leonard lifted his price target on Myriad Genetics (NASDAQ: MYGN) to $46.00 (from $37.00) following solid Q1 results but maintained a Market Perform rating.

Leonard commented, "We are nudging up our FY16 estimates following MYGN's solid September quarter (F1Q),... More

Myriad Genetics (MYGN) Tops Q1 EPS by 6c

November 3, 2015 4:14 PM EST

Myriad Genetics (NASDAQ: MYGN) reported Q1 EPS of $0.41, $0.06 better than the analyst estimate of $0.35. Revenue for the quarter came in at $183.5 million versus the consensus estimate of $177.89 million.

Myriad Genetics sees FY2015 EPS of $1.60-$1.65, versus the consensus of $1.64. Myriad Genetics sees FY2015... More